Background Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …

Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …

Background Activating mutations in serine–threonine protein kinase B-RAF (BRAF) are
found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy …

PURPOSE BRAF/MEK inhibition is a standard of care for patients with BRAF V600E/K–
mutated metastatic melanoma. For patients with less frequent BRAF mutations, however …

BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …

Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset of resistance …

Purpose BRAF mutations promote melanoma cell proliferation and survival primarily through
activation of MEK. The purpose of this study was to determine the response rate (RR) for the …

Dabrafenib and trametinib were approved for use as monotherapies in BRAF-mutant
metastatic melanoma by the US Food and Drug Administration (FDA) in 2013, and most …

The discovery of BRAF mutations in melanoma has not yet translated into clinical success,
suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the …

Treatment with BRAF inhibitors such as vemurafenib or dabrafenib in patients with
advanced BRAFV600 mutated melanoma has shown objective tumor responses in …